Recipients of hematopoietic SCT undergo a period of profound immunosuppression due to the chemotherapy and/or radiotherapy used for the conditioning and to the graft versus host reaction. SCT patients are highly susceptible to the development of viral infections such as CMV or EBV. The achievement of a competent immunological response, such as viral-specific T cells, is associated with a lower incidence of viral infections. Methods for direct identification of antigen-specific T cells have been based on the functional characteristics of these T cells. Techniques such as proliferation and ELISPOT assays, intracellular cytokine staining and IFN-g capture have been used to quantitate and obtain viral-specific T cells. Multimers are composed of several MHC molecules loaded with immunodominant peptides joined to a fluorescent molecule, which signal can be quantified by a flow cytometer. Multimer technology together with recent advances in flow cytometry, have facilitated the monitoring and selection of antigenspecific T cells without the need for in vitro cultures and manipulation. This has resulted in a better characterization of the function and phenotype of the different subpopulations of T cells involved in the immune recovery post allogeneic SCT. It is becoming a distinct possibility to isolate individual antigen-specific T cells, without long-term culture techniques, and potentially use them as adoptive immunotherapy in the SCT setting.
INTRODUCTION
During the initial months post transplant patients remain at a high risk of developing viral diseases due to a profound deficiency of T-cell function induced partly by the immunoablative effect of the conditioning regimen and partly by the complex host versus graft and graft versus host interactions that characterize the immediate post-transplant phase. 1, 2 Other factors contributing to this risk are following: the presence of clinically significant GvHD, steroid or other immunosuppressant use, low circulating CD4 counts, the use of virus-seronegative donors in seropositive patients, T-celldepleted grafts and the use of donors other than HLA-identical siblings (unrelated, haploidentical and cord blood). 1 The administration of antiviral drugs is the standard treatment in cases where a viral infection is presumed or detected. However, antiviral drugs cause multiple side effects, mainly nephrotoxicity and myelosuppression. Moreover, in the case of CMV infections, the use of Ganciclovir has been associated with an increased rate of bacterial sepsis, invasive fungal infections and viral resistance. 1, 2 Therefore, there is an unmet need for alternative treatments. 3 Recently, the use of lymphocyte subpopulations from SCT donors is being considered as a potential new immunotherapy strategy for SCT recipients with high risk of developing viral disease. Initial approaches utilized long-time in vitro cultures to obtain T-cell clones or lines. However, these long-term cultures could potentially modify the functional characteristics of the T cells. More recently, the use of new multimer-based technology as a tool for cellular selection has shown promise in maintaining the function of viral-specific T cells. In this review, we focus on how these new techniques used to isolate viral-specific T cells may affect the phenotype and function of T cells and their potential influence on the long-time persistence of the viral-specific T cells in the recipients after cell transfer. At present, there is no standard process to isolate antigen-specific T cells that preserves the function of these cells before and after the infusion into a patient, thus reducing the risk of viral infection during the initial phases of the post-transplant period.
CMV INFECTION, A MODEL OF VIRAL DISEASE IN HEMATOPOIETIC SCT PATIENTS
CMV infection is by far the most extensively studied post SCT viral infection. Riddell et al. 4 have shown that CMV-specific CD8 þ cytotoxic T-cell clones could be obtained from BM donors using in vitro co-culture of PBMCs from allogeneic donors together with autologous CMV-infected fibroblasts for 5-12 weeks. 5 This group later adoptively transferred the CMV-specific CD8 þ cytotoxic T-cell clones to immunodeficient BMT recipients successfully. With this strategy, no toxicity was seen and the transferred clones provided the same magnitude of lytic activity as that observed in the immunocompetent BM donors for at least 8 weeks after the completion of T-cell therapy. The rearranged Va and Vb genes for the TCR were used to evaluate the survival of the transferred clones in these patients. 6 Similar approaches had also been performed to obtain and expand polyclonal CMV-specific T-cell lines for adoptive immunotherapy. In this setting, the group at NIH has used monocyte-derived dendritic cells pulsed with CMV antigens and co-cultured with PBLs from seropositive donors for CMV. 7, 8 Other groups have utilized virus lysate, recombinant soluble CMVpp65 protein or pool of peptides to prepare CMVspecific T-cell clones 9 A different approach involves the use of gene therapy technology to obtain antigen-specific T cells: retroviral transfer of CMV-specific TCR genes to primary T cells from CMV-negative donors has been able to generate CMVspecific T-cell clones of several HLA restrictions with important effector functions. 10 The common characteristic of these techniques is the extensive cellular culture needed to generate virus-specific T-cell clones.
The effectiveness of adoptive therapy as a treatment strategy for CMV infection post SCT may ultimately depend on generating functional antigen-specific T cells in ways that mimic physiological conditions of a competent immunological system.
EXTENSIVE CULTURE CHANGES THE DIFFERENTIATION STATUS OF ANTIGEN-SPECIFIC CD8 þ T SUBPOPULATIONS
Under physiological conditions, antigen exposure triggers the activation of naive CD8 þ T cells (CTLs), which results in proliferation and progressive differentiation through early, intermediate and late effector stages depending on signal strength.
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Effector T cells (T E ) are derived from other different subset named central memory T cell (T CM ). Antigen-specific memory T cells are generated during this cellular process. 12 These processes could be mimicked in vitro by long-term cultures (Figure 1 ) in which a continuous contact with the specific antigen could induce proliferation and differentiation of T cells into cells with different effector capacities. 13 Lanzavecchia and Sallusto 14 also considered the possibility that cytokines may drive T cells to an antigenindependent slow proliferation. This homeostatic T-cell differentiation may occur in vitro during cellular expansion. TCRtriggering stimulation by antigen exposure, leads to increasing division, altering the pattern of cytokines 15 and thus changing the process of cellular differentiation. Stimulation of antigen-specific CD8 þ T cells using extensive cellular culture under specific antigenic stimulation does not induce a homogeneous cellular product but a high number of subpopulations with diverse differentiation status, different phenotypes and functional and migratory capacities. 16 Thus, Berger et al. 17 showed that antigenspecific CD8 þ T E derived from a subset of memory T cells named effector memory (T EM ) survive for only a short period after adoptive transfer, and failed to home to lymph nodes or BM.
However, T E clones derived from other different subset named T CM persist long term after adoptive transfer, migrate to memory T-cell niches and respond to antigen challenge. Therefore, selection of T CM cells would ensure that after adoptive transfer the cellular product consisting of T E cells would be able to persist durably in vivo and revert to the memory pool. 17, 18 However, acquisition of terminal effector properties and an increase in cytotoxic activity in vitro generate less effective cells at triggering disease regression in vivo. 19 Thus, the more-differentiated cells, with superior in vitro antitumor properties, are less capable of mediating tumor regression upon adoptive transfer. Gattinoni et al. 20 describe the relationship among the duration of in vitro T-cell culture, the functional and phenotypic characteristics of T cells at various stages of differentiation and their immunocompetence upon adoptive transfer. 20, 21 The effectiveness of adoptive therapy to treat viral infection post SCT may ultimately depend on generating functional memory cells in such a way that a competent immunological system mimicking physiological conditions could be reproduced immediately after transplant ( Figure 2 ).
IDENTIFICATION IN VITRO OF MEMORY VIRAL-SPECIFIC T CELLS WITH HIGH EFFECTOR CAPACITY
For the detection of T CM among the viral-specific T-cell pool, it is necessary to clarify the phenotype of these cells and a tool for its direct identification. Several authors have attempted to describe the phenotype of the memory antigen-specific T-cell subpopulation by means of a combination of extracellular and intracellular molecules. In this sense, van Lier et al. 22 defined two discrete Figure 1 . Different approaches have been used to obtain and expand polyclonal CMV-specific T-cell lines for adoptive immunotherapy. In this scheme, monocyte-derived dendritic cells can be pulsed with viral antigens and co-cultured with PBLs from seropositive donors for CMV. Viral lysate, recombinant soluble protein or pooled immunodominat peptides are also used to prepare CMV-specific T-cell clones. A different approach involves the use of gene therapy technology to obtain antigen-specific T cells: retroviral transfer of CMV-specific TCR genes to primary T cells from CMV-negative donors can be used to generate CMV-specific T-cell clones of several HLA restrictions with important effector functions. The common characteristic of these techniques is the extensive cell culture needed to generate virus-specific T-cell clones, resulting in alteration of the cellular differentiation status.
Viral-specific adoptive immunotherapy N Ramírez and E Olavarría primed CD8 þ T-cell subpopulations based on the expression of CD45 isoforms and CD27: CD45RO þ CD27 þ memory cells, which lack immediate cytolytic function, and CD45RA þ CD27 À effector cells with low proliferative capacity and high levels of perforin and cytotoxicity; however, the heterogeneity of these memory subpopulations was revealed by Sallusto et al. 23 with the analysis of CCR7, a chemokine receptor for lymph node homing. This new molecule defines the phenotype of the previously described memory subpopulations: T CM (CCR7 þ CD45RA À ) and T EM (CCR7 À CD45RA À ).
Other authors have also tried to describe the correlation between phenotype and function. Scheinberg et al. 24 assert that the presence of great numbers of less-differentiated CD27( þ )CD57( À )CD8( þ ) CMV-specific T cells in the donor appears to confer protection against viral reactivation in the recipient after hematopoietic SCT. Otherwise, Luo et al. 25 observed that high CMV-specific CTLs with terminally differentiated effector CD45RO À CD62L À cell phenotype in the allografts is associated with a reduced risk of CMV reactivation in the presence of enough CD45RO þ CD62L À effector cell infusion.
Although different groups have investigated the association between the phenotype of memory viral-specific T cells and viral disease protection, there is still a lack of a consensus panel of molecular markers that could define this phenotype.
CLASS I MHC MULTIMERS
The development of the multimer technology has brought a potential tool to detect antigen-specific T cells from the PB of SCT patients. Multimers do not use a phenotypic or functional cellular characteristic to identify viral-specific T cells, but recombinant self-MHC molecules loaded with immunodominant peptides of antigen proteins that are recognized by specific CTLs. Multimers are constituted by several of these MHC molecules joined to a fluorescent molecule that can be quantified by a flow cytometer. The combination of multimers and flow cytometry has been for several years a very useful technique to identify and quantify antigen-specific T cells. Direct visualization, enumeration, phenotypic and functional characterization, isolation and cloning of antigen-specific T cells are the most common applications that may be achieved with this new technology.
Distinct MHC multimer formats: dimers, tetramers, pentamers, streptamers, octamers and dextramers have been developed in the past few years. Differences between multimers are found in just three parameters: the valence of the multimeric complex, the expression system through which the MHC molecules are produced (bacterial or eukaryotic expression systems) and the peptide-loading strategy used to achieve occupancy of the peptide-binding groove with the desired antigenic peptide. 26 The NIH Core Tetramer Facility (http://www.niaid.nih.gov/ reposit/tetramer/index.html) was established in 1999 with the purpose of providing custom synthesis and distribution of soluble human and mouse class I and II MHC tetramers reagents for research. A tetramer is a recombinant molecule with four subunits (tetrameric) of MHC biotinylated. These subunits are folded with the peptide of interest and tetramerized by a fluorescence-labeled streptavidin molecule, which can join up to four biotin molecules. Tetramers can join up to three TCR molecules at once due to the Viral-specific adoptive immunotherapy N Ramírez and E Olavarría tetrahedral disposition of the complex. 27 This is a limiting factor given that all subunits cannot bind at the same time to a specific T cell. This problem has been solved by the pentamers that contain five class I MHC-peptide complexes that are multimerized by a self-assembling coiled coil domain. In this case, all five MHCpeptide complexes face in the same direction resulting in a very high avidity. Low frequency specific T-cell subpopulations are better detected by pentamers due to this high avidity. However, this difference has not increased the sensibility of the technique. In fact, Yao et al. 28 did not find any differences in CMV phosphoprotein 65-specific CD8( þ ) T-cell frequencies using tetramers and pentamers in CMV-seropositive healthy volunteers and CMV-seropositive patients before and after allogeneic PBSC transplantation. Tetramers have been evaluated by the European Working Group on Clinical Cell Analysis, and efforts have been made towards a reproducible assay for routine enumeration of antigen-specific CD8 þ T cells. 29 
ROLE OF THE MULTIMER IN THE REGULATION OF FUNCTION OF ANTIGEN-SPECIFIC T CELL
Most methods for direct selection of T cells require in vitro stimulation of the T cells, which significantly changes their differentiation and functional status as has already been described. Up until recently, it was accepted that multimer technology allowed identification and purification of antigenspecific T cells without altering their differentiation or functional status. However, recent studies with tetramers have provided further evidence that MHC multimer binding interferes with the functional status of epitope-specific T-cell populations in vivo, showing evidence that the usage of MHC multimers can induce epitope-specific tolerance in a dose-dependent manner. After the tetramer and TCR have engaged, a strong 'signal 1' is delivered to antigen-specific T-cell populations and causes an initial expansion of reactive CD8 þ T cells. However, multiple doses of relevant tetramer can reverse the priming effect, suggesting that there is elimination of the tetramer-reactive T cells by clonal exhaustion or anergy. 30 Other authors have observed the unusual functional status of the specific T cells after tetramer selection, given that lytic function and proliferation of the specific T cells was impaired after joining with conventional tetramers. 31 However, this phenomenon of functional disruption has not been observed in vivo conditions. 32 This group found that CMV-specific CTLs selected with tetramer technology and transferred to SCT recipients efficiently contributed to the control of viral replication. 32 In this study, the authors could demonstrate the persistence of CMV-specific CTLs at least 100 days after the infusion, which suggested expansion of the infused cells, not compatible with an anergic status of the cellular product. The same phenomenon was observed in a study in which eight patients received CTLs specific for three different viruses (CMV, adenovirus and EBV) obtained from HLA-identical and haploidentical donors with pentamer technology. Donor-derivedspecific CTLs were detected using chimerism analysis in five out of six evaluable patients. In addition, six patients showed a decrease in viral titers within 2 weeks of CTl infusion. 33 With respect to tetramer multimers, in vitro and in vivo studies show conflicting results when analyzing the functional status of virus-specific CTLs after tetramer selection. On the other hand, there is no in vitro study addressing whether pentamer staining and selection could induce anergy in specific T cells. Pentamer technology uses the same approach that tetramer technology to identify antigen-specific T cells: an interaction between the TCR and MHC-peptide complexes. Therefore, it is theoretically possible that a similar impairment of the T-cell phenotype and function could occur in vitro with pentamers. However, the previously mentioned study shows functional EBV-specific CTLs that are able to remove the EBV-driven lymphoma. 33 As described above, the influence of tetramer and pentamer staining over the function of the T cell remains an important unresolved issue. This is a problem that potentially could limit substantially the clinical applicability of the multimer technology. To address this problem, a reversible human MHC/peptide multimer (streptamer) was constructed by Neudorfer et al. 34 The main characteristic of this multimer is the reversible binding between the streptamer and the TCR of the antigen-specific T cells. The streptamer monomerizes in the presence of a competitor molecule, resulting in rapid release of the staining reagent. Following dissociation, the streptamer-treated CTLs are functionally indistinguishable from untreated T cells. 31 Wang et al. 35 demonstrated that the in vitro treatment of the T cells with peptide-loaded OT-I-streptamers induced an increased proliferation and strong expression of CD69 and CD25 activation markers. It also induced a sustained phosphorylation of Akt (a serine threonine kinase, which is critically involved in T-cell survival) and ERK1/2 (serine/threonine kinase important for cellular proliferation and survival), a weak activation of caspase-3, a weak anexin V and propidium iodide expression and expression of Bcl-x L (that prevents TCR-mediated apoptosis and promotes T-cell survival).
This expression of molecular markers after streptamer engagement supports the idea that streptamer could trigger positive signals for activation and proliferation, in the specific CD8 þ T cells and no functional disruption or tolerance as it has been observed with tetramers. Moreover, streptamers have comparable sensitivity and specificity to conventional tetramers and pentamers, 28, 31 and the streptamer technology additionally offers the advantage of selecting specific T cells under good manufacturing practice conditions for adoptive T-cell transfer. This later aspect has so far proved a significant challenge for translational researchers.
SOLUBLE FACTORS AND CELLULAR MICROENVIRONMENT CHANGE THE FUNCTION OF THE THERAPEUTIC ANTIGEN-SPECIFIC CTLS IN SCT PATIENTS
Homeostatic conditions and the presence of specific lymphocyte subpopulations could alter both the function of circulating therapeutic CTLs after adoptive transfer and the long-term persistence of these cells in the SCT patients.
The lymphopenic environment associated with the early post SCT period is likely to be favorable for T-cell proliferation. It is possible that T cells obtained directly from the donor may be able to expand more efficiently in vivo than in vitro. It has been reported that exposure to viral antigens during the period of profound lymphopenia results in a significant boost in cellular immunity. 32, 36, 37 In this respect, it has been shown that lymphodepletion before adoptive T-cell transfer-based immunotherapies can enhance antitumor responses by depressing the numbers of regulatory T cells, by increasing access to homeostatic cytokines and by augmenting innate immunity, so that the lymphopenic environment could induce qualitative improvements in the adoptively transferred T cells. 38 This phenomenon was first shown by Pittet et al., 39 who observed that both intratumoral CTL accumulation and tumor regression improved when CTLs were injected to lymphopenic animals. Furthermore, regulatory T cells can suppress the activity of effector T cells in different ways: expression of negative costimulatory molecules, induction of antiinflammatory biochemical pathways in effector T cells and APCs, direct or indirect killing of effector cells and APCs, the consumption of proinflammatory cytokines such as IL-2 or the production of immunoregulatory cytokines, such as IL-10, transforming growth factor-b or IL-35. 40 Hence, their eradication in a lymphopenic environment could potentially help the engraftment, expansion and function of the transferred T cells.
Functional status and survival of transferred antigen-specific CTLs depend on specific circulating CD4 þ T cells. One example of Viral-specific adoptive immunotherapy N Ramírez and E Olavarría the limiting role of the antigen-specific CD4 þ T cells in a chronic viral infection is during the pathogenesis of AIDS. HIV-1-infected persons who have no evidence of virus-related clinical disease and low to undetectable viral loads, show a high virus-specific CD4 þ proliferative response and an extremely vigorous CTL response. 41 On the other hand, the resurgence of HIV-infected CD4 þ T cells 7 days after adoptive therapy with HIV-1-specific CTLs correlates with the disappearance of transferred CTLs from the blood, indicating that the transient nature of the antiviral effect reflects the limited in vivo persistence of the transferred CTLs. 42 The exact mechanisms whereby CD4 þ cells contribute to the maintenance of effective antiviral immunity are not known but could be related to an enhanced CTL precursor activity, increased production of antiviral cytokines and augmentation of humoral immune responses. 41 Pourgheysari et al. 43 found a significant correlation between the CMV-specific CD4 þ and CMV-specific CD8 þ T-cell count. They have shown a clear association between reconstitution of the CD4 þ CMV-specific T-cell immune response within the first 50 days post transplantation and protection against CMV reactivation. However, CD8 þ CMV-specific T-cell response was not predictive of protection from a single episode of reactivation, suggesting that reconstitution of CD4 þ CMV-specific T cells has a more important role in the early period post transplantation.
To examine the central role of CMV-specific CD4 þ T cells during the post-transplant period, the development of class II MHC multimers, to measure CD4 þ T cells, is likely to represent a major step forward. 44 However, there are still a number of aspects to improve regarding the applicability of these reagents, in particular the strength of the TCR/pMHC II interactions. 45, 46 TRANSLATIONAL APPLICABILITY OF THE MULTIMER TECHNOLOGY There are many strategies to select antigen-specific CD8 þ T cells for adoptive transfer; however, multimer-based technology has the potential to select antigen-specific T cells from healthy seropositive donors and transfer them directly to the patient without any further manipulation. At present, there are only two published studies that report on adoptive immunotherapy strategies based on tetramers and pentamers. Both describe a successful protocol using multimers and magnetic beads to select CMV-and EBV-specific T cells from healthy donors and transfer them to recipients diagnosed with hematological malignancies. 32 Given that both techniques have obtained excellent results, multimer technology should be considered as a great opportunity to expand adoptive therapy strategies.
In addition, streptamer technology removes the previously raised doubt of the prolonged TCR signaling and subsequently altered T-cell function caused by the irreversible union between the TCR of specific T cell and the multimer. Whether such reversible binding improves the in vivo activity of adoptively transferred T cells remains to be studied.
Two other approximations have recently been presented. The first one used streptamer-based selection available on a good manufacturing practice level to generate Wilms tumor gene 1 (WT1)-specific effector T cells. The primary objective was to generate an improved GVL effect and to minimize the risk of a GvHD WT1-specific CD8 þ T cells were evaluated in a standard 51-chromium release assay for cytotoxicity showing that specific CD8 þ T cells keep cytotoxic properties after cellular selection. However, after this positive selection only a 17.79% of WT1 þ CD8 þ T cells are obtained in the lymphocyte gate 47 In the second approach, streptamer technology allowed the selection of CMV-specific CD3 þ T-cell fraction, with 97% purity. Following the infusion of CMV-specific donor lymphocytes, the CMV antigenemia became negative in a patient with AML. Single joint TCR excision circle analysis revealed peripheral expansion of CTLs transferred and did not stem from intrinsic reconstitution. 48 Both approaches represent a new perspective with respect to the applicability of streptamer-selected CTLs in adoptive immunotherapy.
FUTURE PROSPECTS OF THE MULTIMER TECHNOLOGY
The simultaneous study of extracellular and intracellular molecules in T cells is possible thanks to the advance of the multicolor flow cytometric technology provided by the new generation of flow cytometers and new fluorescence molecules that have been commercialized in recent years. Furthermore, multimer staining could be combined with the study of functional cellular markers to provide a multiparameter phenotypic and/or functional analysis of an antigen-specific T-cell subpopulation. Depending on the researcher's interest, these markers may analyze the activation status (CD69, CD25, CD38, HLA-DR and so on), T-cell subset markers that have been associated with the differentiation cell status (CCR7, CD45RA, CD62L and so on) or expression of other functional molecules (perforin, granzyme, IFN-g, IL-7, TNF-a and so on). The incorporation of these sophisticated cytometers will allow the study of the phenotype and function of specific cells in daily routine samples.
Another major development that could help in the detection of new epitopes is the method for high-throughput parallel detection of antigen-specific T cells by combinatorial encoding of MHC multimers described by Andersen et al. 49 Using this method, a large number of different T-cell populations can be detected in a single sample, and therefore it can be used for T-cell epitope mapping and for the monitoring of CD8-positive immune responses during cancer or infectious disease immunotherapy.
The usual limit of detection of flow cytometry assays is 10
cells. Recently, it has been shown that sensitivity might be increased by 1-log by simply acquiring 10 times more cells compared with standard acquisition conditions without compromising the specificity. 50 Thus, the development of multimer staining in conjunction with the continuing advances in flow cytometry represents an excellent platform to study antigenspecific T-cell subpopulations, which until now have eluded conventional methods in hematological transplant recipients. Monitoring of these cells together with the possibility of simultaneously studying 2-10 cellular markers may help the quantitative and qualitative characterization of the immune response of these patients.
